Retatrutide 20mg

Overview

Retatrutide (LY3437943) is a synthetic peptide analog designed as a triple hormone receptor agonist for controlled laboratory research applications. Unlike single or dual incretin receptor agonists, Retatrutide exhibits high affinity for three distinct receptor targets — the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor — making it a uniquely comprehensive investigative tool for multi-receptor metabolic signaling research.

Scientific investigation of Retatrutide in controlled experimental settings focuses on its biochemical interactions with pancreatic beta-cells, hepatocytes, and adipocytes, with research examining its influence on glucose metabolism pathway dynamics, lipid oxidation mechanisms, and energy homeostasis endpoints. All applications are strictly confined to in-vitro and in-vivo animal research contexts and do not imply clinical, cosmetic, or therapeutic use of any kind.

• Peptide Type: Triple Receptor Agonist (GIP / GLP-1 / Glucagon)

Biochemical Characteristics

• Structure: Chemically modified 39-amino acid peptide backbone with C20 fatty diacid moiety
• Molecular Formula: C₂₂₃H₃₄₃N₄₅O₆₉
• Molecular Weight: ~4,731.33 g/mol
• CAS Number: 2381089-83-2
• PubChem CID: 163340104

Retatrutide incorporates a C20 fatty diacid moiety attached via a linker, which promotes binding to plasma albumin in experimental systems. This biochemical modification is designed to extend the peptide's half-life and stability within controlled laboratory research environments.

Biochemical analyses demonstrate that Retatrutide acts as a potent agonist across all three target receptors simultaneously. By incorporating glucagon receptor activity alongside GIP and GLP-1 receptor engagement, the molecule is studied for its unique ability to influence energy expenditure pathway dynamics and mitochondrial function endpoints — characteristics distinct from earlier generations of mono- and dual-receptor agonist research compounds.

Research Applications

Retatrutide is utilized in laboratory research to investigate metabolic signaling pathways involving insulin secretion dynamics, glucagon suppression mechanisms, and hepatic lipid metabolism endpoints. Experimental systems include:

• Diet-induced obesity (DIO) rodent research models
• Hepatocyte culture systems for hepatic steatosis pathway research
• Glycemic regulation control assay systems
• Lipolysis regulation pathway investigation
• Mitochondrial turnover endpoint research in adipose tissue models
• White adipose tissue browning pathway investigation
• Fatty acid oxidation transcriptional network analysis in hepatic research models
• Comparative receptor internalization rate analysis versus established dual-agonist reference compounds under controlled experimental conditions
• Multi-receptor synergistic metabolic hormone signaling pathway studies

Pathway & Mechanistic Context

Mechanistic studies document Retatrutide as a modulator of multiple biochemical pathways simultaneously in controlled laboratory settings:

GLP-1 & GIP Receptor Pathway Activity
Activation of GLP-1 and GIP receptors in experimental systems influences insulin signaling cascades, gastric motility marker endpoints, and glucose-dependent insulin secretion pathway dynamics.

Glucagon (GCG) Receptor Pathway Activity
GCG receptor activation in preclinical research models is investigated for its role in thermogenesis pathway dynamics and energy expenditure endpoint modulation — a mechanistic characteristic not accessible through single or dual incretin receptor agonist research compounds.

Transcriptional Network Modulation
Gene-expression analyses demonstrate that Retatrutide influences transcriptional networks associated with:

• Fatty acid oxidation pathway activity in hepatic research models
• White adipose tissue browning and thermogenic gene expression endpoints
• Mitochondrial function and energy metabolism pathway markers

The simultaneous engagement of three receptor systems allows researchers to investigate synergistic effects of multi-receptor metabolic hormone signaling under controlled laboratory conditions not replicable with single-receptor ligand compounds.

Preclinical Research Summary

Preclinical investigations of Retatrutide include extensive studies in murine models of obesity and non-alcoholic fatty liver disease (NAFLD). Commonly evaluated experimental endpoints include:

• Body weight trajectory and composition endpoint assessments
• Hepatic fat fraction and liver metabolism markers
• Plasma lipid profile endpoint measurements
• Energy balance and metabolic rate endpoint dynamics
• Hepatic lipid clearance pathway markers
• Glycemic regulation index modulation in controlled animal research systems
• Comparative multi-receptor versus mono-agonist endpoint analysis to quantify additive mechanistic value of glucagon receptor engagement

All findings are presented exclusively as controlled laboratory observations and do not imply clinical or therapeutic outcomes of any kind.

Form & Analytical Testing

Retatrutide is supplied as a synthetic research-grade peptide for controlled laboratory workflows. Product identity and purity are confirmed using:

• HPLC — purity profiling and lot consistency verification
• Mass Spectrometry (MS) — molecular identity confirmation

Batch-specific documentation is provided where applicable to verify the absence of fillers and confirm peptide structural integrity.

Purity & Quality

• ≥99% Purity — HPLC Verified
• Independently tested by accredited third-party laboratory
• Certificate of Analysis (CoA) available for every batch

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.

All Retatrutide research compounds supplied by P1 Peptides are produced using lyophilization — also known as cryodesiccation — a specialized dehydration process widely employed in the manufacture of research-grade synthetic peptide materials.

During this process, the peptide is first frozen and then subjected to reduced pressure conditions, allowing residual moisture to sublimate directly from solid to vapor phase. This yields a stable, crystalline dry powder that preserves full structural integrity of the peptide compound throughout the storage period.

In its lyophilized form, Retatrutide research compounds remain stable for up to 3–4 months when stored properly under recommended conditions prior to reconstitution.

Reconstitution

When research protocols require reconstitution, Retatrutide is typically prepared using bacteriostatic water under controlled laboratory conditions. Once reconstituted, the peptide solution must be refrigerated to maintain compound stability. Reconstituted solutions are generally stable for up to 30 days when stored appropriately under refrigeration.

All reconstitution procedures should be carried out in accordance with standard laboratory protocols applicable to synthetic peptide research materials.

Recommended Storage Guidelines

The following storage parameters are recommended to maintain compound integrity throughout the research lifecycle:

Short-Term Storage — Unopened Lyophilized Vials

• Upon Receipt — Store in a cool, dry environment away from direct light and heat sources
• Short-Term Use (immediate use to several weeks or months) — Refrigeration below 4°C (39°F) is generally sufficient to maintain compound integrity
• Room Temperature Storage — Lyophilized Retatrutide is typically stable at room temperature for several weeks, making ambient storage acceptable for short-term laboratory use prior to reconstitution

Long-Term Storage — Unopened Lyophilized Vials

• Extended Storage (several months to years) — Freezing at −80°C (−112°F) is the preferred method for preserving compound stability and structural integrity over extended periods

Post-Reconstitution Storage

• Store reconstituted solutions under refrigeration below 4°C (39°F), away from direct light
• Do not freeze reconstituted solutions
• Discard any unused reconstituted material after 30 days or upon observation of cloudiness, discoloration, or particulate matter

Additional Laboratory Guidance

For specific storage requirements applicable to this research compound, researchers should consult the Certificate of Analysis (CoA) provided with each batch, as well as applicable peer-reviewed literature and institutional laboratory protocols governing synthetic peptide handling and storage procedures.

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.